Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of Enstilar® in Daily Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years of age~* Psoriasis vulgaris~* Lesions on trunk and/or extremities of at least mild severity~* Treatment with Enstilar® planned~* Signed informed consent to participate~Exclusion Criteria:~* Enrolled in any interventional clinical trial~* Ongoing or recent treatment with any systemic psoriasis~* Ongoing or recent treatment with UV-therapy~* Ongoing or previous treatment with Enstilar®~* Psoriasis of scalp only~* Other forms of psoriasis, e.g. erythrodermic or pustular psoriasis~* More than 30% of surface area affected by psoriasis~* Any contraindications or known allergies to Enstilar® or its ingredients~* Incapacitated patients under institutionalized care

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enstilar® (Type: None): Patients with psoriasis vulgaris plaques on body and/or extremities will apply Enstilar® (calcipotriol /betamethasone dipropionate (50 micrograms/g + 0.5 mg/g) cutaneous foam) once daily for up to 4 weeks, according to the approved labelling of Enstilar® in Germany.

Based on this trial design, predict the completion outcome and termination type (if applicable).